149 related articles for article (PubMed ID: 38650383)
1. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.
Chen H; Guan X; He C; Lu T; Lin X; Liao X
Expert Opin Ther Targets; 2024 Apr; 28(4):237-250. PubMed ID: 38650383
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).
Linney ID; Kaila N
Expert Opin Ther Pat; 2021 Oct; 31(10):893-910. PubMed ID: 33956554
[No Abstract] [Full Text] [Related]
3. The development of small-molecule inhibitors targeting HPK1.
Zhou L; Wang T; Zhang K; Zhang X; Jiang S
Eur J Med Chem; 2022 Dec; 244():114819. PubMed ID: 36209628
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective.
Zhu Q; Chen N; Tian X; Zhou Y; You Q; Xu X
J Med Chem; 2022 Jun; 65(12):8065-8090. PubMed ID: 35696642
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.
Wang Y; Zhang K; Georgiev P; Wells S; Xu H; Lacey BM; Xu Z; Laskey J; Mcleod R; Methot JL; Bittinger M; Pasternak A; Ranganath S
PLoS One; 2020; 15(12):e0243145. PubMed ID: 33270695
[TBL] [Abstract][Full Text] [Related]
6. The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.
Hernandez S; Qing J; Thibodeau RH; Du X; Park S; Lee HM; Xu M; Oh S; Navarro A; Roose-Girma M; Newman RJ; Warming S; Nannini M; Sampath D; Kim JM; Grogan JL; Mellman I
Cell Rep; 2018 Oct; 25(1):80-94. PubMed ID: 30282040
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.
Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Higuchi S
Biochem Biophys Res Commun; 2024 Jun; 715():149995. PubMed ID: 38685185
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Wu F; Li H; An Q; Sun Y; Yu J; Cao W; Sun P; Diao X; Meng L; Xu S
Eur J Med Chem; 2023 Jun; 254():115355. PubMed ID: 37062169
[TBL] [Abstract][Full Text] [Related]
9. A perspective on HPK1 as a novel immuno-oncology drug target.
Sawasdikosol S; Burakoff S
Elife; 2020 Sep; 9():. PubMed ID: 32896273
[TBL] [Abstract][Full Text] [Related]
10. The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy.
Malchow S; Korepanova A; Panchal SC; McClure RA; Longenecker KL; Qiu W; Zhao H; Cheng M; Guo J; Klinge KL; Trusk P; Pratt SD; Li T; Kurnick MD; Duan L; Shoemaker AR; Gopalakrishnan SM; Warder SE; Shotwell JB; Lai A; Sun C; Osuma AT; Pappano WN
ACS Chem Biol; 2022 Mar; 17(3):556-566. PubMed ID: 35188729
[TBL] [Abstract][Full Text] [Related]
11. Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation.
Ahn MJ; Kim EH; Choi Y; Chae CH; Kim P; Kim SH
PLoS One; 2024; 19(6):e0305261. PubMed ID: 38923962
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D; Hillerman S; Locke G; Chaudhry C; Stromko C; Murtaza A; Fan Y; Koenitzer J; Chen Y; Briceno S; Bhadra R; Duperret E; Gullo-Brown J; Gao C; Zhao D; Feder J; Curtin J; Degnan AP; Kumi G; Wittman M; Johnson BM; Parrish KE; Gokulrangan G; Morrison J; Quigley M; Hunt JT; Salter-Cid L; Lees E; Sanjuan MA; Liu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408094
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
[TBL] [Abstract][Full Text] [Related]
14. Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1.
Arnold R; Patzak IM; Neuhaus B; Vancauwenbergh S; Veillette A; Van Lint J; Kiefer F
Mol Cell Biol; 2005 Mar; 25(6):2364-83. PubMed ID: 15743830
[TBL] [Abstract][Full Text] [Related]
15. HPK1 as a novel target for cancer immunotherapy.
Sawasdikosol S; Zha R; Yang B; Burakoff S
Immunol Res; 2012 Dec; 54(1-3):262-5. PubMed ID: 22477524
[TBL] [Abstract][Full Text] [Related]
16. Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Taniguchi T; Umezaki Y; Nakazawa Y; Uesugi S; Mori K; Horiuchi T; Obuchi W; Minami M; Shimada T; Wada C; Yoshida T; Higuchi S
Eur J Pharmacol; 2023 Dec; 961():176184. PubMed ID: 37944847
[TBL] [Abstract][Full Text] [Related]
17. Interactions between hematopoietic progenitor kinase 1 and its adaptor proteins (Review).
Zhang Q; Ding S; Zhang H
Mol Med Rep; 2017 Nov; 16(5):6472-6482. PubMed ID: 28901492
[TBL] [Abstract][Full Text] [Related]
18. Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay.
Wang W; Mevellec L; Liu A; Struble G; Miller R; Allen SJ; Federowicz K; Wroblowski B; Vialard J; Ahn K; Krosky D
Biochemistry; 2021 Oct; 60(41):3114-3124. PubMed ID: 34608799
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors.
Fu S; Wei J; Li C; Zhang N; Yue H; Yang A; Xu J; Dong K; Xing Y; Tong M; Shi X; Xi Z; Wang H; Hou Y; Zhao Y
Bioorg Chem; 2024 Jul; 148():107454. PubMed ID: 38795581
[TBL] [Abstract][Full Text] [Related]
20. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Shi H; Tang H; Li Y; Chen D; Liu T; Chen Y; Wang X; Chen L; Wang Y; Xie H; Xiong B
Eur J Med Chem; 2023 Feb; 248():115064. PubMed ID: 36621137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]